Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's Sarcoma cells In vitro

Cancer Research

Volumn 70, Issue 10, 2010, Pages 4015-4023

  Aryee, Dave N T ^a   Niedan, Stephan ^a   Kauer, Maximilian ^a   Schwentner, Raphaela ^a   Bennani Baiti, Idriss M ^a   Ban, Jozef ^a   Muehlbacher, Karin ^a   Kreppel, Michael ^a   Walker, Robert L ^b   Meltzer, Paul ^b   Poremba, Christopher ^c   Kofler, Reinhard ^d   Kovar, Heinrich ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Research Park Trier   (Germany)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTOME;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; EWING SARCOMA; GENE INDUCTION; HYPOXIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; UPREGULATION;

ANOXIA; BLOTTING, WESTERN; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SARCOMA, EWING'S; TRANSCRIPTIONAL ACTIVATION; TUMOR MARKERS, BIOLOGICAL;

EID: 77952801325     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4333     Document Type: Article

References (48)

1. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732
2. Semenza GL. O2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1. J Appl Physiol 2004;96: 1173-7; discussion 0-2.
3. Kim JW, Gao P, Dang CV. Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev 2007;26:291-298
4. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 2007;26:319-331
5. Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 2004;57: 1009-1014
6. Denko NC, Fontana LA, Hudson KM, et al. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 2003;22:5907-5914 (Pubitemid 37176711)
7. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998; 95:7987-7992 (Pubitemid 28326053)
8. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008;15:678-685
9. Denko N, Wernke-Dollries K, Johnson AB, Hammond E, Chiang CM, Barton MC. Hypoxia actively represses transcription by inducing negative cofactor 2 (Dr1/DrAP1) and blocking preinitiation complex assembly. J Biol Chem 2003;278:5744-5749 (Pubitemid 36800819)
10. Kitamuro T, Takahashi K, Ogawa K, et al. Bach1 functions as a hypoxia-inducible repressor for the heme oxygenase-1 gene in human cells. J Biol Chem 2003;278:9125-9133 (Pubitemid 36800393)
11. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999;59:5830-5835
12. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485-490 (Pubitemid 28373960)
13. Salnikow K, Costa M, Figg WD, Blagosklonny MV. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer. Cancer Res 2000;60:5630-5634
14. Zhong H, Agani F, Baccala AA, et al. Increased expression of hypoxia inducible factor-1α in rat and human prostate cancer. Cancer Res 1998;58:5280-5284 (Pubitemid 28551099)
15. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxiainducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61: 2911-2916
16. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-4696
17. Koukourakis MI, Giatromanolaki A, Skarlatos J, et al. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 2001;61:1830-1832 (Pubitemid 32691993)
18. Kovar H, Ban J, Pospisilova S. Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. Semin Cancer Biol 2003;13:275-281 (Pubitemid 38160919)
19. Bailly RA, Bosselut R, Zucman J, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 1994; 14:3230-3241 (Pubitemid 24132736)
20. Beauchamp E, Bulut G, Abaan O, et al. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem 2009;284:9074-9082
21. Lessnick SL, Dacwag CS, Golub TR. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 2002;1:393-401.
22. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet 1997;17:495-497 (Pubitemid 27518406)
23. Zwerner JP, Guimbellot J, May WA. EWS/FLI function varies in different cellular backgrounds. Exp Cell Res 2003;290:414-419 (Pubitemid 37272183)
24. Cironi L, Riggi N, Provero P, et al. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One 2008;3:e2634.
25. Guillon N, Tirode F, Boeva V, Zynovyev A, Barillot E, Delattre O. The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PLoS One 2009;4:e4932.
26. Hancock JD, Lessnick SL. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 2008;7:250-256
27. Kauer M, Ban J, Kofler R, et al. A molecular function map of Ewing's sarcoma. PLoS One 2009;4:e5415.
28. Potikyan G, France KA, Carlson MR, Dong J, Nelson SF, Denny CT. Genetically defined EWS/FLI1 model system suggests mesenchymal origin of Ewing's family tumors. Lab Invest 2008;88:1291-1302
29. Staege MS, Hutter C, Neumann I, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 2004;64:8213-8221 (Pubitemid 39491758)
30. Lawlor ER, Scheel C, Irving J, Sorensen PH. Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors. Oncogene 2002;21:307-318 (Pubitemid 34102139)
31. Bosco MC, Puppo M, Blengio F, et al. Monocytes and dendritic cells in a hypoxic environment: spotlights on chemotaxis and migration. Immunobiology 2008;213:733-749
32. Kovar H. Context matters: the hen or egg problem in Ewing's sarcoma. Semin Cancer Biol 2005;15:189-196 (Pubitemid 40501733)
33. Gort EH, van Haaften G, Verlaan I, et al. The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2α. Oncogene 2008;27: 1501-1510 (Pubitemid 351347879)
34. Aryee DN, Kreppel M, Bachmaier R, et al. Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo. Cancer Res 2006;66:9862-9869
35. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
36. Wu Z, Irizarry R, Gentleman R, Martinez-Murillo F, Spencer F. A model based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 2004;99:909-917 (Pubitemid 39665934)
37. Kim SY, Volsky DJ. PAGE: parametric analysis of gene set enrichment. BMC Bioinformatics 2005;6:144.
38. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately down-regulated in human diabetes. Nat Genet 2003;34:267-273
39. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102:15545-15550 (Pubitemid 41528093)
40. Ackerstaff E, Artemov D, Gillies RJ, Bhujwalla ZM. Hypoxia and the presence of human vascular endothelial cells affect prostate cancer cell invasion and metabolism. Neoplasia 2007;9:1138-1151 (Pubitemid 350255361)
41. Uren A, Toretsky JA. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent. Future Oncol 2005;1: 521-528
42. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
43. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-7.
44. Favaro E, Nardo G, Persano L, et al. Hypoxia inducible factor-1α inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death. Am J Pathol 2008;173:1186-1201
45. Riggi N, Suva ML, Suva D, et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008;68:2176-2185 (Pubitemid 351521790)
46. Benini S, Zuntini M, Manara MC, et al. Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. Int J Cancer 2006;119:1039-1046 (Pubitemid 44116910)
47. Kilic M, Kasperczyk H, Fulda S, Debatin KM. Role of hypoxia inducible factor-1 α in modulation of apoptosis resistance. Oncogene 2007;26:2027-2038 (Pubitemid 46514744)
48. Kenneth NS, Rocha S. Regulation of gene expression by hypoxia. Biochem J 2008;414:19-29.